Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Prices $4.8M Stock Offering

NEW YORK (GenomeWeb News) – Response Genetics has launched a public offering of nearly 4.5 million shares of its common stock at $1.20 per share.

The Los Angeles-based molecular diagnostics firm said that it expects to raise about $4.8 million in net proceeds, which it will use for working capital and general corporate purposes. It could realize additional proceeds if underwriters of the offering exercise their over-allotment option of 669,666 shares.

The offering price is below Thursday's closing price on the Nasdaq of $1.32, and shares of Response Genetics dropped nearly 11 percent to $1.18 in early Friday trade after the offering was priced.

Last month the firm announced a 24 percent decline in Q3 revenues year over year and ended the quarter with $4.6 million in cash and cash equivalents. It subsequently announced that it had signed on four payors to provide access to the molecular diagnostic firm's tests.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more